Mecasermin [rDNA origin] Injection Articles
Ipsen reveals positive findings with rhGH and Increlex
16 September 2009
Ipsen's revenues up 6% on new US launches
9 February 2009
Ipsen reports 8.4% sales growth in 1st qtr
12 May 2008
Tercica begins dosing in Ph II IGF-1 deficiency trial
4 February 2008
Ipsen/Tercica's Increlex approved in Europe
20 August 2007
Tercica and Genentech sign R&D deal
16 July 2007
Tercica in manufacturing deal with Lonza
21 May 2007
Ipsen nine-months sales up 8.8%
6 November 2006
Ipsen to move into USA via Tercica
31 July 2006
Ipsen and Increlex enter global endocrinology accord
24 July 2006
EC grants orphan status to Tercica's Increlex
12 June 2006
Tercica sells 5M shares to raise $30M
30 January 2006
Tercica launches Increlex in USA
9 January 2006
Tercica submits Increlex MAA
19 December 2005
Tercica responds to citizen petition
5 September 2005
FDA OKs Tercica's Increlex for primary IGFD
5 September 2005
Insmed files Citizen Petition to block Tercica's Increlex
22 August 2005
Tercica moves to block Insmed growth drug in USA
6 June 2005
Priority review for Tercica's growth agent
9 May 2005
Showing 1-28 of 28 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
